Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study

Authors
Publication date
Publisher
Wolters Kluwer Medknow Publications

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions

    Newcastle University E-Prints

    redirect
    oaioai:eprints.ncl.ac.uk:292568
    Last time updated on 14/08/2023